Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

NewsGuard 100/100 Score
Nov 30 2010

Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that data regarding Marqibo for treatment of adults with relapsed/refractory acute lymphoblastic leukemia (ALL) will be the subject of two presentations at the 2010 Annual Meeting and Exposition of the American Society of Hematology (ASH) being held in Orlando, Florida from December 4-7, 2010.

Presentation details are as follows:

Abstract: 2142: Marqibo® (vincristine sulfate liposomes injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) In Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL)

Abstract: 2143: Marqibo® (vincristine sulfate liposomes injection; VSLI) In the Treatment of Adult Patients with Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06 and RALLY Studies

The abstracts are available online at:

http://ash.confex.com/ash/2010/webprogram/Paper33455.html
http://ash.confex.com/ash/2010/webprogram/Paper34609.html

Source: Hana Biosciences, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Novel therapeutic approach identified for overcoming resistance in B-cell leukemia
Innovative therapy targets and destroys leukemia stem cells
Concomitant pharmacotherapy overcomes immunotherapy challenges in aggressive blood cancer
ABT199/venetoclax synergism with thiotepa enhances cytotoxicity of chemo drugs in AML cells
Rising survival rates for AML patients over 65 after allogeneic hematopoietic stem cell transplant
European experts publish recommendations for treatment of acute lymphoblastic leukemia in adults
City of Hope cures oldest person of blood cancer and achieves HIV remission
Study reveals genetic variant linked to increased risk of leukemia in Hispanic/Latino children

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Novel approach improves CAR T-cell therapy efficacy against acute myeloid leukemia